Retatrutide: Maintained at established dose (typically 8 to 12 mg weekly) BPC-157: 0.25 mg daily TB-500: 2.5 mg twice weekly (loading) or 2 mg weekly (maintenance) GHK-Cu: 0.1 to 0.2 mg three times weekly Duration: 8 to 12 weeks maximum, with 30-day minimum break between cycles The injection schedule for the complete GLOW protocol requires careful organization
This product is intended strictly for analytical and experimental research in properly managed non-clinical laboratory settings
Please note: For Intramuscular (IM) or Intravenous (IV) use only Store away from direct sunlight 1 ~ 25C Keep out of sight and reach of children Not intended to diagnose, treat, cure or prevent any disease, for promoting wellness only This is a single use ampoule, once opened, use immediately and discard any product not used All products are for sale to trained and insured professionals only who are 18+ years of age
For the CY 2026 OPPS, we do not believe that the procedures being removed from the IPO list would require the level 5 Endovascular Procedures APC that the commenter requested
Injecting in a post-absorptive state keeps the signaling environment cleaner and consistent across all 10 doses
The preservative extends shelf life and provides antimicrobial protection during repeated withdrawals
